BrightSpring Health Services appoints Dr. Steve Miller to Board of Directors

BrightSpring Health Services, Inc.

Dr. Steve Miller appointed as Class II director on September 27, 2024; board expands from 7 to 8 members.
Miller will serve on Audit Committee and chair Quality & Compliance and Governance Committee.
Former Chief Clinical Officer of Cigna (2018-2022) and CMO of Express Scripts (2005-2018).
No transactions requiring disclosure under Item 404(a) between Miller and the company.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Steve Miller

Class II director

BTSG · BrightSpring Health Services, Inc.

Effective: 2024-09-27
Filed: September 30, 2024, 7:59 PM ET

On September 27, 2024, the board of directors (the “Board”) of BrightSpring Health Services, Inc. (the “Company”) increased the number of directors serving on the Board from seven (7) to eight (8) members and appointed Dr. Steve Miller to the Board as a Class II director to fill the resulting vacancy.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Steve Miller was appointed as Class II director at BrightSpring Health Services, Inc..

Action: appointed
Role: Class II director

Exact text from the filing

On September 27, 2024, the board of directors (the “Board”) of BrightSpring Health Services, Inc. (the “Company”) increased the number of directors serving on the Board from seven (7) to eight (8) members and appointed Dr. Steve Miller to the Board as a Class II director to fill the resulting vacancy.

View on SEC.gov

BrightSpring Health Services, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-110168

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.